potential

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…

20 hours ago

ORIC Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 20:00 ET  | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…

3 days ago

Fenova uPVC Door & Window Systems Recognized by Forbes India DGEMS as a SELECT 200 Company with Global Business Potential

SOLAPUR, India, Dec. 3, 2025 /PRNewswire/ -- Fenova uPVC Door & Window Systems, a division of Arihant Profile – Extrusion…

5 days ago

Crypto Mondays Austin Presents: Regenerative Wealth Where Blockchain, Wellness, Fashion, and Human Potential Meet

Austin, TX, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Crypto Mondays Austin announces Regenerative Wealth, an innovative gathering that merges technology,…

2 weeks ago

Xinhua Silk Road: Unleashing digital potential to unlock new vitality of liquor industry

BEIJING, Oct. 31, 2025 /PRNewswire/ -- Amid the wave of the digital economy, new-generation digital technologies such as cloud computing,…

1 month ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…

1 month ago

PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…

2 months ago

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…

2 months ago

CytoMed makes cash bid for potential acquisition of TC BioPharm Limiteds relevant assets

SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical…

2 months ago